Efficacy of bevacizumab-containing chemotherapy in metastatic colorectal cancer and CXCL5 expression: Six case reports

BACKGROUND: In metastatic colorectal cancer (mCRC), the anti-vascular endothelial growth factor drug bevacizumab (BVZ) plus chemotherapy significantly improves progression-free survival compared to chemotherapy (CT) alone. This benefit is not, however, observed in all patients. While increased chemo...

Descripción completa

Detalles Bibliográficos
Autores principales: Novillo, Apolonia, Gaibar, María, Romero-Lorca, Alicia, Gilsanz, María Fuencisla, Beltrán, Laura, Galán, Miguel, Antón, Beatriz, Malón, Diego, Moreno, Amalia, Fernández-Santander, Ana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7201148/
https://www.ncbi.nlm.nih.gov/pubmed/32390708
http://dx.doi.org/10.3748/wjg.v26.i16.1979

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7201148/
https://www.ncbi.nlm.nih.gov/pubmed/32390708
http://dx.doi.org/10.3748/wjg.v26.i16.1979

Ejemplares similares